Kluyveromyces marxianus YZC-01 preparation for degrading uric acid and application thereof
Through the fermentation culture and enzyme extraction and preparation of Max Cluvia YZC-01 strain, a method of efficient biodegradation of uric acid is provided, which solves the problems of poor degradation effect and side effects of uric acid in the prior art, and achieves safe and effective uric acid removal.
Patent Information
- Application Number
- CN202410539518.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-30
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-04-30
AI Technical Summary
The prior art has no significant effect in degrading uric acid and has side effects, making it difficult to effectively control hyperuricemia.
A strain of Max Kluvieris YZC-01 and its preparation are provided, which can efficiently biodegrade uric acid, and prepare liquid or solid preparations through fermentation culture and enzyme extraction for the degradation of uric acid.
Max Kluvier's YZC-01 strain can degrade 2g/L of uric acid within 72 hours. The enzyme produced achieves complete degradation of uric acid within 24 hours, and is safe for the human body, providing a high efficiency with fewer side effects. Method for reducing uric acid.
Smart Images

Figure CN118931741A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology and relates to a Kluyveromyces marxianus YZC-01 preparation for degrading uric acid and a preparation method and application thereof. Background Art
[0002] In recent years, the number of gout patients in my country caused by increased uric acid (Serum uric acid) levels has increased dramatically, posing a serious threat to people's health. Uric acid is the end product of purine metabolism in the human body. Its molecular formula is C5H4N4O3, molecular weight is 168, slightly soluble in water, and easy to form crystals. About 80% of uric acid in the human body is produced by the synthesis of endogenous small molecule compounds and the catabolism of purine nucleotides, and the remaining 20% of uric acid is produced by the degradation of exogenous purines ingested in food.
[0003] Under normal conditions, the production and excretion of uric acid in the human body basically maintain a dynamic balance. However, due to the lack of urate oxidase, uric acid cannot be degraded into more soluble allantoin, which hinders the excretion of uric acid through the kidneys and intestines. Excessive production of uric acid or insufficient excretion will lead to increased blood uric acid levels in the human body, resulting in hyperuricemia. The diagnostic criteria are: fasting blood uric acid levels are higher than the threshold (male>420μmol / L, female>360μmol / L) twice on different days. Uric acid, as the final product of purine metabolism, can be degraded into water-soluble allantoin by urate oxidase in non-primates and is easily excreted. However, due to the lack of urate oxidase in humans and primates, uric acid is not easily decomposed, resulting in blood uric acid levels that are 3-10 times higher than non-primates. This is also the main reason why humans are prone to hyperuricemia and gout.
[0004] At present, the treatment or improvement of hyperuricemia is mainly divided into drug therapy and dietary intervention. Drug therapy is the most common way to control hyperuricemia. Commonly used drugs include allopurinol, febuxostat, benzbromarone and urate oxidase (rasburicase, purikacil), etc., which mainly reduce the production of uric acid by inhibiting the activity of xanthine oxidase or increase the excretion of uric acid by reducing the reabsorption of uric acid, so as to control the level of blood uric acid. The main mechanism of action of urate oxidase is to further degrade uric acid into more soluble allantoin, so it is easily excreted from the kidneys. Although chemical drugs can play a certain role in controlling hyperuricemia, a series of side effects such as allergic reactions, liver damage, and abnormal renal function cannot be ignored. Dietary intervention mainly relieves hyperuricemia by limiting the intake of high-purine foods, beer and fructose. Although it can control the level of blood uric acid to a certain extent, the effect is not ideal. Therefore, studying safer and more efficient methods to control hyperuricemia has become a key scientific research problem that needs to be solved in the current biomedical field. Summary of the invention
[0005] One of the purposes of the present invention is to address the problem that the drugs or foods for degrading and removing uric acid in the prior art are not effective and have side effects, and to provide a Kluyveromyces marxianus YZC-01 strain for degrading uric acid. The bacterial cells of the strain and the enzymes produced by the strain are safe for the human body, and both can efficiently biodegrade uric acid, and have important application prospects in removing uric acid.
[0006] The second object of the present invention is to provide a Kluyveromyces marxianus YZC-01 preparation for degrading uric acid and its application. The Kluyveromyces marxianus YZC-01 preparation is made from the above-mentioned Kluyveromyces marxianus YZC-01 strain for biodegrading uric acid and can efficiently biodegrade uric acid.
[0007] To this end, the first aspect of the present invention provides a Kluyveromyces marxianus YZC-01 strain for degrading uric acid, which is capable of producing an enzyme that catalyzes the degradation of uric acid, and its deposit number is CGMCC No.29514.
[0008] In some embodiments of the present invention, the Kluyveromyces marxianus YZC-01 strain can completely degrade and remove uric acid with an initial concentration of 2 g / L within 72 hours at an initial bacterial cell concentration of 2×10 7 / mL.
[0009] In other embodiments of the present invention, the crude enzyme produced by the Kluyveromyces marxianus strain YZC-01 can completely remove uric acid with an initial concentration of 2 g / L within 24 hours at a protein concentration of 8.0 mg / mL.
[0010] The second aspect of the present invention provides a Kluyveromyces marxianus YZC-01 preparation for degrading uric acid, which contains bacterial cells and / or crude enzymes of the Kluyveromyces marxianus YZC-01 strain as described in the first aspect of the present invention; preferably, the Kluyveromyces marxianus YZC-01 preparation contains the Kluyveromyces marxianus YZC-01 strain as described in the first aspect of the present invention.
[0011] In some embodiments of the present invention, the uric acid-degrading Kluyveromyces marxianus YZC-01 preparation is a liquid preparation; preferably, in the liquid preparation for degrading uric acid, the bacterial cell concentration of the Kluyveromyces marxianus YZC-01 strain is (2-5)×107 / mL; and / or, in the liquid preparation for degrading uric acid, the protein concentration of the crude enzyme of the Kluyveromyces marxianus YZC-01 strain is 5-10 mg / mL.
[0012] In other embodiments of the present invention, the uric acid-degrading Kluyveromyces marxianus YZC-01 preparation is a solid powder preparation; preferably, in the solid powder preparation for degrading uric acid, the content of bacterial cells of the Kluyveromyces marxianus YZC-01 strain is (1-6)×107 / g, more preferably (2-5)×107 / g; and / or, in the solid powder preparation for degrading uric acid, the protein content of the crude enzyme of the Kluyveromyces marxianus YZC-01 strain is 5-10 mg / g, more preferably 8-10 mg / g.
[0013] The third aspect of the present invention provides a method for preparing the Kluyveromyces marxianus YZC-01 preparation for degrading uric acid as described in the second aspect of the present invention, comprising:
[0014] Step B, inoculating the fermentation bacteria into a fermentation medium for fermentation culture to obtain a fermentation culture of Kluyveromyces marxianus YZC-01 strain;
[0015] Step C, centrifuging the fermentation culture of Kluyveromyces marxianus YZC-01 strain to harvest bacterial cells of Kluyveromyces marxianus YZC-01 strain;
[0016] The fermentation strain is obtained by seed culture of the corresponding Kluyveromyces marxianus YZC-01 strain. According to the present invention, the fermentation medium, based on 1L of water, includes the following components in 1L of water:
[0017] Peptone 5-10g; preferably 8-10g;
[0018] Yeast powder 5-10g; preferably 8-10g; and
[0019] Glucose 3-8g; preferably 4-6g;
[0020] Preferably, the pH value of the fermentation medium is 7-8;
[0021] Further preferably, in step B, the fermentation culture temperature is 18-40°C, preferably 30-35°C.
[0022] According to some embodiments of the present invention, the preparation method further comprises:
[0023] Step K, subjecting the cell suspension of the Kluyveromyces marxianus YZC-01 strain to cell disruption treatment under low temperature conditions to obtain a cell-free disruption solution of the Kluyveromyces marxianus YZC-01 strain;
[0024] Step L, centrifuging the cell-free disrupted liquid of Kluyveromyces marxianus YZC-01 strain, and taking the supernatant cell-free extract as the crude enzyme of Kluyveromyces marxianus YZC-01 strain;
[0025] Wherein, the low temperature is 0-4°C.
[0026] The fourth aspect of the present invention provides a use of the Kluyveromyces marxianus YZC-01 preparation for degrading uric acid according to the second aspect of the present invention or the Kluyveromyces marxianus YZC-01 preparation for degrading uric acid prepared by the preparation method according to the third aspect of the present invention in the preparation of a uric acid-lowering agent, comprising:
[0027] Step D, washing the bacterial cells of Kluyveromyces marxianus YZC-01 strain with physiological saline to obtain pure bacterial cells of Kluyveromyces marxianus YZC-01 strain;
[0028] Step E, in a physiological saline system, under low temperature conditions, using ultrasound to disrupt the pure bacterial cells of Kluyveromyces marxianus YZC-01 strain, and taking the supernatant after centrifugation to obtain a cell-free extract as a crude enzyme pure product of Kluyveromyces marxianus YZC-01 strain;
[0029] Step F, freeze-drying the pure bacterial cell product and / or the pure crude enzyme product of Kluyveromyces marxianus YZC-01 strain, and diluting the freeze-dried Kluyveromyces marxianus YZC-01 preparation to prepare a uric acid-degrading agent;
[0030] Wherein, the low temperature is 0-4°C.
[0031] In some embodiments of the present invention, in step F, the freeze-dried Kluyveromyces marxianus YZC-01 preparation is diluted with physiological saline to prepare a liquid uric acid-lowering agent.
[0032] In other embodiments of the present invention, in step F, the freeze-dried Kluyveromyces marxianus YZC-01 preparation is diluted with edible starch to prepare a solid uric acid-lowering agent.
[0033] In some preferred embodiments of the present invention, the uric acid lowering agent is an oral preparation.
[0034] Studies have found that the Kluyveromyces marxianus YZC-01 strain for biodegrading uric acid and the enzyme produced by the present invention are safe for the human body and can biodegrade uric acid. They have important application prospects in the efficient removal of uric acid for the treatment of human hyperuricemia and corresponding complications. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] In order to make the present invention easy to understand, the present invention is described below with reference to the accompanying drawings.
[0036] Figure 1The molecular evolution tree of Kluyveromyces marxianus YZC-01 based on 18S rDNA is shown.
[0037] Figure 2 This is the kinetic curve of biodegradation of uric acid by Kluyveromyces marxianus YZC-01.
[0038] Figure 3 This is the kinetic curve of uric acid degradation catalyzed by Kluyveromyces marxianus YZC-01 enzyme.
[0039] Strain preservation
[0040] Kluyveromyces marxianus was isolated and identified by Beijing Beike Yiran Biotechnology Co., Ltd. and has been deposited in the General Microbiological Center of China Microbiological Culture Collection Committee (referred to as: CGMCC; address: Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing), deposit date: January 4, 2024, deposit number: CGMCC No. 29514. In the present invention, the strain is named Kluyveromyces marxianus strain YZC-01, also known as Kluyveromyces marxianus YZC-01. DETAILED DESCRIPTION
[0041] To make the present invention easy to understand, the present invention will be described in detail below. However, before describing the present invention in detail, it should be understood that the present invention is not limited to the specific embodiments described. It should also be understood that the terms used herein are only for describing specific embodiments and are not intended to be limiting.
[0042] Unless otherwise defined, all terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, preferred methods and materials are now described.
[0043] I. Terminology
[0044] The term "bacteria" as used in the present invention refers to living cells and / or dead cells of Kluyveromyces marxianus.
[0045] The term "crude enzyme" used in the present invention refers to a cell-free extract obtained by disrupting Kluyveromyces marxianus cells and centrifuging the supernatant.
[0046] The term "pure crude enzyme" used in the present invention refers to a cell-free extract obtained by breaking the pure bacterial cells of Kluyveromyces marxianus and taking the supernatant through centrifugation.
[0047] The term "microbial preparation" used in the present invention refers to various forms of preparations that are made from microorganisms with medical research value using traditional technology or modern biotechnology and act on the prevention (health care), treatment and diagnosis of various physiological symptoms of the human body.
[0048] The term "edible starch" as used in the present invention refers to starch that meets the "National Standard for Edible Starch" (GB 31637-2016 National Food Safety Standard Edible Starch).
[0049] The "water" used in the culture medium or fermentation culture process of the present invention, unless otherwise specified, refers to sterile pure water obtained by filtering through a 0.22μ filter membrane.
[0050] II. Implementation Plan
[0051] As mentioned above, the existing diet and drug therapy for controlling uric acid in the human body has slow and insignificant effects and has side effects. Therefore, the inventors have conducted a lot of in-depth research on the biodegradation of uric acid.
[0052] The inventors have noted that although lactic acid bacteria can promote intestinal health and reduce the accumulation of uric acid to some extent through a series of metabolic adjustments, there are no reports on the bacteria used to directly and efficiently biodegrade uric acid.
[0053] In recent years, the study of human microorganisms has been a hot topic and frontier in life science research. Although domestic and foreign scholars have screened out microbial strains that can inhibit uric acid synthesis and degrade uric acid precursors such as inosine and guanosine from traditional foods, no evidence has been found that Kluyveromyces marxii can directly and efficiently biodegrade uric acid.
[0054] The inventors also noted that Kluyveromyces marxianus is a eukaryotic microorganism and is a yeast that is approved by the National Health Commission of my country for direct consumption. Although Kluyveromyces marxianus can promote human intestinal health and improve human immune function, it has been widely used in the fields of food, fermentation, beer and beverage production, but no research reports on its biodegradation of uric acid have been found so far.
[0055] Based on long-term microbial research, the inventor successfully screened a strain of Kluyveromyces marxianus YZC-01 from healthy human intestinal bacteria. The inventor found through research and exploration that the strain cells and the enzymes produced can completely degrade the initial concentration of 2g / L uric acid within 72h and 24h respectively, which not only has very important research value, but also has important application prospects in the efficient biodegradation and removal of uric acid. The present invention is obtained thereby.
[0056] Therefore, the Kluyveromyces marxianus YZC-01 strain for biodegrading uric acid according to the first aspect of the present invention can produce an enzyme that catalyzes the degradation of uric acid.
[0057] The inventors first successfully screened a strain of Kluyveromyces marxianus YZC-01 from the intestinal flora of healthy humans. After extracting genomic DNA, it was determined to be Kluyveromyces marxianus through PCR amplification and molecular identification based on 18S rDNA sequencing. Based on the above, the strain was identified and named Kluyveromyces marxianus strain YZC-01. The strain has been deposited in the General Microbiological Center of the China Microbiological Culture Collection Administration, with the deposit number: CGMCC No. 29514.
[0058] The inventors have found that during fermentation of Kluyveromyces marxianus YZC-01 strain, yeast cells produced during the fermentation process contain more than one enzyme capable of catalyzing the degradation of uric acid. In the present invention, the mixture of these enzymes is referred to as crude enzyme, or Kluyveromyces marxianus YZC-01 crude enzyme.
[0059] Further research found that the cell-free lysate after yeast cell disruption was centrifuged and the supernatant cell-free extract was taken as the crude enzyme of Kluyveromyces marxianus YZC-01. It is easy to understand that both the cells and crude enzyme of Kluyveromyces marxianus YZC-01 strain can catalyze the degradation of uric acid.
[0060] The results showed that the Kluyveromyces marxianus YZC-01 strain had an initial bacterial cell concentration of 2×10 7 / mL, the initial concentration of uric acid of 2g / L can be completely degraded and removed within 72 hours.
[0061] The crude enzyme produced by the Kluyveromyces marxianus YZC-01 strain can completely degrade uric acid with an initial concentration of 2 g / L within 24 hours at a protein concentration of 8.0 mg / mL.
[0062] Based on the above, the second to fourth aspects of the present invention further provide the use or application of the Kluyveromyces marxianus for biodegrading uric acid as described in the first aspect of the present invention.
[0063] Specifically, the second aspect of the present invention provides a Kluyveromyces marxianus YZC-01 preparation for biodegrading uric acid, which is a microbial preparation for biodegrading uric acid, and contains bacterial cells and / or crude enzymes of the Kluyveromyces marxianus YZC-01 strain as described in the first aspect of the present invention.
[0064] In some preferred embodiments of the present invention, the Kluyveromyces marxianus YZC-01 preparation contains bacterial cells of the Kluyveromyces marxianus YZC-01 strain as described in the first aspect of the present invention.
[0065] According to some embodiments of the present invention, the Kluyveromyces marxianus YZC-01 preparation for biodegrading uric acid is a liquid preparation.
[0066] In some embodiments of the present invention, in the liquid preparation for biodegradation of uric acid, the bacterial cell concentration of Kluyveromyces marxianus YZC-01 strain is (2-5)×10 7 / mL.
[0067] In other embodiments of the present invention, in the liquid preparation for biodegradation of uric acid, the protein concentration of the crude enzyme of Kluyveromyces marxianus YZC-01 strain is 5-10 mg / mL.
[0068] According to other embodiments of the present invention, the Kluyveromyces marxianus YZC-01 preparation for biodegrading uric acid is a solid powder preparation.
[0069] In some embodiments of the present invention, in the solid powder preparation for biodegradation of uric acid, the bacterial cell content of Kluyveromyces marxianus YZC-01 strain is (1-6)×10 7 / g, preferably (2-5)×10 7 / g.
[0070] In other embodiments of the present invention, in the solid powder preparation for biodegradation of uric acid, the protein content of the crude enzyme of Kluyveromyces marxianus YZC-01 strain is 5-10 mg / g, preferably 8-10 mg / g.
[0071] The third aspect of the present invention provides a method for preparing the Kluyveromyces marxianus YZC-01 preparation for biodegrading uric acid as described in the second aspect of the present invention, comprising:
[0072] Step B, inoculating the fermentation bacteria into a fermentation medium, and fermenting and culturing at 18-40° C., preferably 30-35° C., and a shaking speed of 100-300 rpm for 3-5 days to obtain a fermentation culture of Kluyveromyces marxianus YZC-01 strain;
[0073] Step C, centrifuging the fermentation culture of Kluyveromyces marxianus YZC-01 strain to harvest bacterial cells of Kluyveromyces marxianus YZC-01 strain;
[0074] The fermentation strain is obtained by seed culture of the corresponding Kluyveromyces marxianus YZC-01 strain.
[0075] As those skilled in the art know, currently, 18S rRNA is commonly used internationally for molecular identification of eukaryotic microorganisms, so 18S rRNA can be used for comparison to obtain homology in similarity comparison. Therefore, the fermentation strain used in the present invention is not limited to the field isolate used in the present invention. 18S rDNA is a DNA sequence corresponding to rRNA encoded on bacterial chromosomes, and exists in the chromosome genome of all eukaryotic microorganisms. Figure 1 The molecular evolutionary tree of Kluyveromyces marxianus strain YZC-01 based on 18S rDNA is shown.
[0076] In the above step C, the centrifugal separation treatment includes resuspending and washing the precipitate (i.e., bacterial cells of Kluyveromyces marxianus YZC-01 strain) obtained by centrifugal separation of the liquid fermentation culture with physiological saline, and then centrifuging it to obtain bacterial cells of Kluyveromyces marxianus YZC-01 strain.
[0077] The present invention has no particular limitation on the conditions for centrifugal separation in the above step C. In some embodiments of the present invention, for example, the substance to be separated may be centrifuged at 8000-10000 r / min for 10 min.
[0078] According to the method of the present invention, the fermentation culture is a shaking table or fermentation tank fermentation culture of the strain, and the fermentation strain is inoculated into the fermentation medium in the form of seed liquid. The inoculation amount of the seed liquid is 0.1%-1% (v / v); preferably, the inoculation amount of the seed liquid is 0.2%-0.5% (v / v); more preferably, the inoculation amount of the seed liquid is 0.5% (v / v).
[0079] Specifically, the fermentation medium comprises the following components in 1L of water:
[0080] Peptone 5-10g;
[0081] 5-10g yeast powder; and
[0082] Glucose 3-8g.
[0083] Preferably, the fermentation medium comprises the following components in 1L of water:
[0084] Peptone 8-10g;
[0085] 8-10g yeast powder; and
[0086] Glucose 4-6g.
[0087] In some embodiments of the present invention, the initial pH of the fermentation medium is adjusted to 6-8 using 40% (wt / v) sodium hydroxide solution and 36% (v / v) hydrochloric acid solution.
[0088] According to some embodiments of the present invention, the preparation method of the Kluyveromyces marxianus YZC-01 preparation involved in the present invention also includes a seed culture step A before step B: picking the monoclonal colony of the Kluyveromyces marxianus YZC-01 strain provided by the present invention and inoculating it into 100 mL of fermentation liquid culture medium, and culturing it on a shaking table at a temperature of 30°C and a rotation speed of 200r / min for 3 days to obtain a fermentation strain (seed liquid).
[0089] The inventors studied the effects of different temperatures on the growth of Kluyveromyces marxianus YZC-01 and found that Kluyveromyces marxianus YZC-01 grew faster at a temperature of 30°C.
[0090] According to some embodiments of the present invention, the preparation method further comprises:
[0091] Step K, subjecting the cell suspension of the Kluyveromyces marxianus YZC-01 strain to cell disruption in an ice-water bath (i.e., an ice-water mixture, 0-4° C.) to obtain a cell-free disruption solution of the Kluyveromyces marxianus YZC-01 strain;
[0092] Step L: centrifuge the cell-free disrupted liquid of Kluyveromyces marxianus YZC-01 strain, and take the supernatant cell-free extract as the crude enzyme of Kluyveromyces marxianus YZC-01 strain.
[0093] The present invention has no particular limitation on the conditions for centrifugal separation in the above step L. In some embodiments of the present invention, for example, the separation material may be centrifuged at 15000-18000 r / min for 10-20 min.
[0094] The fourth aspect of the present invention provides a use of the Kluyveromyces marxianus YZC-01 preparation for biodegrading uric acid according to the second aspect of the present invention or the Kluyveromyces marxianus YZC-01 preparation for biodegrading uric acid prepared by the preparation method according to the third aspect of the present invention in the preparation of a uric acid-lowering agent, comprising:
[0095] Step D, washing the bacterial cells of Kluyveromyces marxianus YZC-01 strain with physiological saline to obtain pure bacterial cells of Kluyveromyces marxianus YZC-01 strain;
[0096] Step E, in a physiological saline system, at a low temperature of 0°C to 4°C, using ultrasound to disrupt the pure bacterial cells of Kluyveromyces marxianus YZC-01 strain, and taking the supernatant after centrifugation to obtain a cell-free extract as a crude enzyme pure product of Kluyveromyces marxianus YZC-01 strain;
[0097] Step F, freeze-drying the pure bacterial cells and / or the pure crude enzyme of Kluyveromyces marxianus YZC-01 strain, and diluting the freeze-dried Kluyveromyces marxianus YZC-01 preparation to prepare a uric acid-lowering agent.
[0098] In some embodiments of the present invention, in step F, the freeze-dried Kluyveromyces marxianus YZC-01 preparation is diluted with physiological saline to prepare a liquid uric acid-lowering agent.
[0099] In other embodiments of the present invention, in step F, the freeze-dried Kluyveromyces marxianus YZC-01 preparation is diluted with edible starch to prepare a solid uric acid-lowering agent.
[0100] In some preferred embodiments of the present invention, the uric acid lowering agent is an oral preparation.
[0101] III. Related materials and detection methods in the present invention
[0102] 1. Materials
[0103] The healthy human intestinal fecal bacteria capsule samples involved in the present invention were purchased from Beijing Fumate Biotechnology Co., Ltd., and a license for use in research and development activities was obtained.
[0104] 2. Detection method
[0105] (1) The cell concentration in the present invention is determined by the following method:
[0106] To determine the cell concentration of Kluyveromyces marxianus YZC-01, the culture of Kluyveromyces marxianus YZC-01 was diluted a certain multiple with physiological saline, and the cell concentration was directly determined using a flow cytometer (SYSMEX, Germany).
[0107] (2) The uric acid concentration in the present invention is determined by the following method:
[0108] The uric acid concentration was determined by high performance liquid chromatography (Shimadzu LC-20AT), specifically, the chromatographic column was Kromasil C18 (4.6×250 mm, 5 μ particle size); the mobile phase was methanol: 0.5% acetic acid aqueous solution (10:90); the detection wavelength was 283 nm; the flow rate was 1 mL / min; the injection volume was 20 μL; and the temperature was 35°C.
[0109] (3) The crude enzyme protein concentration in the present invention is measured by the following method:
[0110] The cell-free extract of Kluyveromyces marxianus YZC-01 was diluted a certain number of times with phosphate buffer solution, and Coomassie Brilliant Blue G-250 dye reagent was added in proportion to react for 10 minutes. The absorbance was measured at 595 nm using a 722S visible spectrophotometer (Shanghai Lingguang), and the protein concentration was calculated using the standard curve method.
[0111] III. Examples
[0112] The present invention is described in detail below through specific examples. The experimental methods described below, unless otherwise specified, are all routine laboratory methods. The experimental materials described below, unless otherwise specified, can all be obtained from commercial channels.
[0113] Embodiment 1:
[0114] (1) Prepare a growth medium for Kluyveromyces marxianus YZC-01, the composition of which is (per liter): 10.0 g of peptone, 10.0 g of yeast powder, and 5.0 g of glucose. Add 100 ml of the prepared liquid medium into a 500 ml Erlenmeyer flask, sterilize at high temperature and high pressure (121°C) for 20 minutes, and then sterilize under ultraviolet light in a clean bench for another 20 minutes.
[0115] (2) Under sterile conditions in a clean bench, 0.5 ml of Kluyveromyces marxianus YZC-01 bacterial culture was inoculated into a liquid culture medium in a triangular flask, and batch culture was carried out at a temperature of 30°C and a shaking speed of 200 rpm for 3 days. The Kluyveromyces marxianus YZC-01 cells were harvested by centrifugation (8000 rpm, 10 minutes) and the supernatant was discarded.
[0116] Take 20mL of Kluyveromyces marxianus YZC-01 cell suspension, add it to a 50mL glass tube and insert it into ice water, and use an ultrasonic cell disruptor to disrupt the Kluyveromyces marxianus YZC-01 cells. The conditions are: ultrasonic power 400W, interval 2 seconds, ultrasonic oscillation 10 seconds, and disruption time 15 minutes (5 minutes each time). After the cell disruption is completed, the cell disruption solution is centrifuged at 15000 rpm for 20 minutes, and then the supernatant is slowly poured out as a cell-free extract (crude enzyme) of Kluyveromyces marxianus YZC-01.
[0117] (3) According to different uric acid concentrations, the cultured Kluyveromyces marxianus YZC-01 cells and crude enzymes were added in a certain proportion as a fast, safe and efficient biocatalyst to achieve the purpose of rapid and efficient degradation and removal of uric acid.
[0118] Figure 1 The results showed that the strain we screened was most closely related to Kluyveromyces marxianus, so it was named Kluyveromyces marxianus YZC-01 strain.
[0119] Figure 2 The initial cell concentration of Kluyveromyces marxianus YZC-01 was 2.0×10 7 / mL, the initial concentration of uric acid of 2 g / L can be completely degraded within 72 hours, indicating that Kluyveromyces marxianus YZC-01 has a strong biodegradation ability for uric acid.
[0120] Figure 3 The results showed that the cell-free extract (crude enzyme) of Kluyveromyces marxianus YZC-01 could catalyze the degradation of uric acid at a faster rate. At a protein concentration of 8.0 mg / mL, the initial concentration of uric acid of 2 g / L could be completely degraded within 24 hours, indicating a higher uric acid degradation rate.
[0121] It should be noted that the embodiments described above are only preferred embodiments of the present invention, which are used to explain the present invention and do not constitute any limitation to the present invention. The present invention has been described with reference to typical embodiments, but it should be understood that the words used therein are descriptive and explanatory words, rather than restrictive words. The present invention may be modified as specified within the scope of the claims of the present invention, and the present invention may be revised without departing from the scope and spirit of the present invention. Although the present invention described therein relates to specific methods, materials and embodiments, it does not mean that the present invention is limited to the specific examples disclosed therein. On the contrary, the present invention can be extended to all other methods and applications with the same functions.
Claims
1. A Kluyveromyces marxianus YZC-01 strain for degrading uric acid, which can produce an enzyme that catalyzes the degradation of uric acid, and whose deposit number is CGMCC No.29514.
2. The Kluyveromyces marxianus strain YZC-01 according to claim 1, characterized in that The Kluyveromyces marxianus YZC-01 strain was prepared at an initial bacterial cell concentration of 2×10 7 / mL, the initial concentration of uric acid of 2g / L can be completely degraded and removed within 72 hours.
3. The Kluyveromyces marxianus strain YZC-01 according to claim 1, characterized in that The crude enzyme produced by the Kluyveromyces marxianus YZC-01 strain can completely remove uric acid with an initial concentration of 2 g / L within 24 hours at a protein concentration of 8.0 mg / mL.
4. A Kluyveromyces marxianus YZC-01 preparation for degrading uric acid, comprising bacterial cells and / or crude enzymes of the Kluyveromyces marxianus YZC-01 strain as claimed in any one of claims 1 to 3; preferably, the Kluyveromyces marxianus preparation comprises the Kluyveromyces marxianus YZC-01 strain as claimed in any one of claims 1 to 3.
5. The Kluyveromyces marxianus YZC-01 preparation according to claim 4, characterized in that The uric acid-degrading Kluyveromyces marxianus YZC-01 preparation is a liquid preparation; preferably, in the uric acid-degrading liquid preparation, the bacterial cell concentration of the Kluyveromyces marxianus YZC-01 strain is (2-5)×10 7 / mL; and / or, in the liquid preparation for degrading uric acid, the protein concentration of the crude enzyme of Kluyveromyces marxianus YZC-01 strain is 5-10 mg / mL; Alternatively, the uric acid-degrading Kluyveromyces marxianus YZC-01 preparation is a solid powder preparation; preferably, in the uric acid-degrading solid powder preparation, the content of bacterial cells of Kluyveromyces marxianus YZC-01 strain is (1-6)×10 7 / g, more preferably (2-5)×10 7 / g; and / or, in the solid powder preparation for degrading uric acid, the protein content of the crude enzyme of Kluyveromyces marxianus YZC-01 strain is 5-10 mg / g, more preferably 8-10 mg / g.
6. A method for preparing the Kluyveromyces marxianus YZC-01 preparation for degrading uric acid as claimed in any one of claims 4 or 5, comprising: Step B, inoculating the fermentation bacteria into a fermentation medium for fermentation culture to obtain a fermentation culture of Kluyveromyces marxianus YZC-01 strain; Step C, centrifuging the fermentation culture of Kluyveromyces marxianus YZC-01 strain to harvest bacterial cells of Kluyveromyces marxianus YZC-01 strain; The fermentation strain is obtained by seed culture of the corresponding Kluyveromyces marxianus YZC-01 strain.
7. The preparation method according to claim 6, characterized in that: The fermentation medium, based on 1L of water, includes the following components in 1L of water: Peptone 5-10g; preferably 8-10g; Yeast powder 5-10g; preferably 8-10g; as well as Glucose 3-8g; preferably 4-6g; Preferably, the pH value of the fermentation medium is 7-8; Further preferably, in step B, the fermentation culture temperature is 18-40°C, preferably 30-35°C.
8. The preparation method according to claim 6 or 7, characterized in that: The preparation method further comprises: Step K, subjecting the cell suspension of the Kluyveromyces marxianus YZC-01 strain to cell disruption treatment under low temperature conditions to obtain a cell-free disruption solution of the Kluyveromyces marxianus YZC-01 strain; Step L, centrifuging the cell-free disrupted liquid of Kluyveromyces marxianus YZC-01 strain, and taking the supernatant cell-free extract as the crude enzyme of Kluyveromyces marxianus YZC-01 strain; Wherein, the low temperature is 0-4°C.
9. Use of the uric acid-degrading Kluyveromyces marxianus YZC-01 preparation according to claim 4 or 5 or the uric acid-degrading Kluyveromyces marxianus YZC-01 preparation obtained by the preparation method according to any one of claims 6 to 8 in the preparation of a uric acid-lowering agent, comprising: Step D, washing the bacterial cells of Kluyveromyces marxianus YZC-01 strain with physiological saline to obtain pure bacterial cells of Kluyveromyces marxianus YZC-01 strain; Step E, in a physiological saline system, under low temperature conditions, using ultrasound to disrupt the pure bacterial cells of Kluyveromyces marxianus YZC-01 strain, and taking the supernatant after centrifugation to obtain a cell-free extract as a crude enzyme pure product of Kluyveromyces marxianus YZC-01 strain; Step F, freeze-drying the pure bacterial cell product and / or the pure crude enzyme product of Kluyveromyces marxianus YZC-01 strain, and diluting the freeze-dried Kluyveromyces marxianus YZC-01 preparation to prepare a uric acid-degrading agent; Wherein, the low temperature is 0-4°C.
10. The use according to claim 9, characterized in that: In step F, the freeze-dried Kluyveromyces marxianus YZC-01 preparation is diluted with physiological saline to prepare a liquid uric acid-lowering agent; Alternatively, in step F, the freeze-dried Kluyveromyces marxianus YZC-01 preparation is diluted with edible starch to prepare a solid uric acid-lowering agent; Preferably, the uric acid lowering agent is an oral preparation.
Citation Information
Patent Citations
Novel acetobacter and gluconacetobacter strains and their metabolites for use in inhibiting xanthine oxidase
CN107058034A
Method for brewing fruit cider by utilizing kluyveromyces marxianus
CN112251311A
Kluyveromyces marxianus YZC-01 preparation for degrading L-homocysteine and application of Kluyveromyces marxianus YZC-01 preparation
CN118207105A
Composition for lowering serum uric acid level
CN1812801A
Health functional food composition using pear young fruit
KR1020130004456A
Cited By
Kluyveromyces marxianus with uric acid reducing function and application of kluyveromyces marxianus
CN121109160A
